Bliss GVS Pharma Limited
Bliss GVS Pharma Limited engages in the development, manufacturing and marketing of pharmaceutical formulations in India and internationally. It offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotion, lozenges, nasal solutions, oral solids, parenterals, pessarie… Read more
Bliss GVS Pharma Limited (BLISSGVS) - Total Liabilities
Latest total liabilities as of September 2025: ₹2.32 Billion INR
Based on the latest financial reports, Bliss GVS Pharma Limited (BLISSGVS) has total liabilities worth ₹2.32 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bliss GVS Pharma Limited - Total Liabilities Trend (2005–2025)
This chart illustrates how Bliss GVS Pharma Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Bliss GVS Pharma Limited Competitors by Total Liabilities
The table below lists competitors of Bliss GVS Pharma Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Talga Group Ltd
PINK:TLGRF
|
USA | $6.61 Million |
|
Vaxcell-Bio Therapeutics Co. Ltd
KQ:323990
|
Korea | ₩5.28 Billion |
|
Beijing Liven Technology Co. Ltd.
SHE:001259
|
China | CN¥120.05 Million |
|
Tornado Global Hydrovacs Ltd
V:TGH
|
Canada | CA$64.04 Million |
|
ReposiTrak
NASDAQ:TRAK
|
USA | $5.44 Million |
|
SMCP S.A.S.
LSE:0RVA
|
UK | €1.01 Billion |
|
Nexen Tire Prf 1
KO:002355
|
Korea | ₩2.95 Trillion |
Liability Composition Analysis (2005–2025)
This chart breaks down Bliss GVS Pharma Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.46 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.98 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bliss GVS Pharma Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bliss GVS Pharma Limited (2005–2025)
The table below shows the annual total liabilities of Bliss GVS Pharma Limited from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹2.09 Billion | -0.90% |
| 2024-03-31 | ₹2.11 Billion | -11.92% |
| 2023-03-31 | ₹2.39 Billion | -8.71% |
| 2022-03-31 | ₹2.62 Billion | +5.39% |
| 2021-03-31 | ₹2.49 Billion | -10.69% |
| 2020-03-31 | ₹2.79 Billion | +13.73% |
| 2019-03-31 | ₹2.45 Billion | -21.55% |
| 2018-03-31 | ₹3.12 Billion | -28.69% |
| 2017-03-31 | ₹4.38 Billion | +38.58% |
| 2016-03-31 | ₹3.16 Billion | +1.89% |
| 2015-03-31 | ₹3.10 Billion | +8.56% |
| 2014-03-31 | ₹2.86 Billion | -8.80% |
| 2013-03-31 | ₹3.13 Billion | +216.21% |
| 2012-03-31 | ₹990.86 Million | +111.39% |
| 2011-03-31 | ₹468.74 Million | +81.64% |
| 2010-03-31 | ₹258.05 Million | -12.16% |
| 2009-03-31 | ₹293.78 Million | +1.69% |
| 2008-03-31 | ₹288.90 Million | -15.16% |
| 2007-03-31 | ₹340.53 Million | +832.79% |
| 2006-03-31 | ₹36.51 Million | +56.99% |
| 2005-03-31 | ₹23.25 Million | -- |